Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 9/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633274 | 0.78 | PRKCQ (0.45) | PRKCQSYKSRCZAP70 | |
| SCHEMBL1632083 | 0.71 | IKBKB (0.47) | SYKBRD4 | |
| SCHEMBL13363203 | 0.68 | PRKCQ (0.53) | PRKCQSYKBRD4EIF2AK4 | |
| SCHEMBL1871031 | 0.68 | PRKCQ (0.53) | PRKCQBRD4EIF2AK4 | |
| SCHEMBL13498327 | 0.68 | IKBKB (0.43) | SYKBRD4 | |
| SCHEMBL1634267 | 0.67 | CDK4 (0.50) | SRCBRD4MAP4K1 | |
| SCHEMBL3504389 | 0.67 | PRKCQ (0.49) | PRKCQSRCBRD4EIF2AK4 | |
| SCHEMBL3504386 | 0.66 | PRKCQ (0.51) | PRKCQBRD4EIF2AK4 | |
| SCHEMBL1635190 | 0.66 | SYK (0.49) | SYKSRCZAP70 | |
| SCHEMBL1634175 | 0.66 | SYK (0.53) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | PRKCQ 150/4885SYK 4204/4885SRC 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.